THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

ELDAR-FINKELMAN Hagit

Serial No.:

10/810,578

Filed:

March 29, 2004

For: GLYCOGEN SYNTHASE KINASE-3 INHIBITORS

\$\text{c} \text{c} \t

Examiner:

Group Art Unit: 1645

Attorney

Docket: 27457

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This application is a Divisional of 09/951,902 filed 09/14/2001 which is a CIP of PCT/US01/00123 filed 01/03/2001. Applicant requests that MPEP 609 be complied with and the examiner consider information which has been considered by the Office in a parent application when examining (A) a continuation application, (B) a divisional application, or (C) a continuation-in-part application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfull/submitted,

Registration No. 25,457

Dated: March 31, 2005

APR 1 TOTE AND ENDER OF THE PARTY OF THE PAR

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1993, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)						Complete if Known						
						ation Numbe	r 10/810,578					
						Date		September 14, 2001				
						amed Invent	or	ELDAR-FINKELMAN				
						it						
						ner Name		_				
Sheet	Sheet 1 of				Attorne	Attorney Docket Number 274		27457	7457			
U.S. PATENT DOCUMENTS												
Examiner Initials*	Cite No. 1	Document Number		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
		Number-Kind Code ^{2 (if known)}										
	1	US-6,153,618	11-28-2000		Schultz et al.							
	2	US-6,057,117	02-2-2000		Harrison et al.							
	1											
									<u> </u>			
										_		
				_			_					
							_					
			FOREIC	N PAT	ENT DO	CUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known) PCT WO 98/16528		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
	3			04-23-	1998	Schultz et al.						
-	4 PCT WO 01/49709		07-12-2001		Eldar-Finkleman							
	5	PCT WO 01/49/09 PCT WO 02/24941 PCT WO 00/59206		03-28-2002 05-5-2000 03-3-2000 12-14-2000		Biondi et al. Mendlovic et al. Cohen-Or et al. Rosenthal et al.						
	6											
	7	PCT WO 00/35200										
	8	PCT WO 00/43237	_									
-		101 000/74003						_				
	 			-						-		
 			-	†			-					
 -				† 	· ···							
Examine	r T			الـ		' -	Date			1		
Signature							Conside	ered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

equired to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995

	Su	bstitute for form 1449A/PTO	Complete Application Number	10/810,578									
	INTE	ODMATION DISCLOSUDE	Filing Date	September 14, 2001									
		ORMATION DISCLOSURE	First Named Inventor	ELDAR-									
	STA	ATEMENT BY APPLICANT	Thist rained inventor	FINKELMAN									
		(use as many sheets as necessary)	Group Art Unit	1645									
		(use as many siteets as necessary)	Examiner Name										
Sheet	2	Of 2	Attorney Docket Number	27457									
	+=	OTHER PRIOR ART – NON PATENT LITE	RATURE DOCUMENTS										
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the	article (when appropriate), title of										
Initials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.											
	9	Eldar-Finkleman et al. "The Insulin Mimetic Action of Glycogen Synthase Kinase-3											
		Inhibitors", Diabetologia, 45(Suppl.2): A 70, 38 th Annual Meeting for the European											
		Association for the Study of Diabetes (EASD), Budapest, Hungary, 2002. Abstract.											
	10	Plotkin et al. "Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors											
		of Glycogen Synthase Kinase-3", Journal of Pharmacology and Experimental											
		Therapeutics, 305(3): 974-980, 2003.											
	11	Leclerc et al. "Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two											
		Proteins Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's											
		Disease", The Journal of Biological Chemistry, 276(
	12	Hotamisligil et al. "IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase											
		Activity in TNT-α- and Obesity-Induced Insulin Resi	istance", Science, 271: 665	-,									
	13	Tanti et al. "Serine/Threonine Phosphorylation of Ins											
		Modulates Insulin Receptor Signaling", The Journal	of Biological Chemistry, 20	59(8):									
		6051-6057, 1994.											
	14	Fahraeus et al. "Inhibition of PRB Phosphorylation a	nd Cell-Cycle Progression	by a									
		20-Residue Peptide Derived from P16 CDKN2/INK4	4A", Current Biology, 6(1)	: 84-									
		91, 1996.											
	15	Mitchell et al. "Heat-Stable Inhibitor Protein Derived	l Peptide Substrate Analogs	s:									
		Phosphorylation by amp-Dependent and cGMP-De	pendent Protein Kinases",	Am.									
		Chemical Soc., 1994.											
	16	Maniatis "Signal Transduction: Catalysis by a Multip	orotein IkB Kinase Comple	x",									
		Science, 278(5339): 818, 1997. Extract.											
	27	American Diabetes Association "Standards of Medic											
		Diabetes Mellitus", Diabetes Care, 17(6): 616-623, 1	994										
	28	Hawiger, J., "Non-Invasive Intracellular Delivery of											
		Opin. Chem. Biol., 3:89-94, 1999											

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Signature

Considered

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.